Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of TSU-68 for Advanced Hepatocellular Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 20-74~* PS 0-2~* Patients who did not respond to surgery, RFA, TAE, chemotherapy, or radiotherapy~* Chid-Pugh A or B~* At least one measurable lesion by RECIST criteria~Exclusion Criteria:~* Large amount of pleural effusion or ascites~* Esophageal varices~* Simultaneously active double cancer

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Orantinib

Based on this trial design, predict the completion outcome and termination type (if applicable).